CPDR is a program of the Uniformed Services University of the Health Sciences
and the Henry M. Jackson Foundation for the Advancement of Military Medicine

< Publications Archive

> 1996 Publications

1-10

 

11. The role of the p53 tumor suppressor gene in prostate cancer: a possible biomarker?
Heidenberg HB, Bauer JJ, McLeod DG, Moul JW, and Srivastava S:
Urology 48:971-979, 1996.

 

12. Teleconferencing as a method of educating men about managing advanced prostate cancer and pain.
Glajchen M, and Moul JW:
J Psychosocial Oncol, 14 (2):73-87, 1996.

 

13. Patient selection for experimental adjuvant therapy after radical prostatectomy (letter).
Douglas TH, McCarthy WF, McLeod DG, and Moul JW:
Urology, 47:284-285, 1996.

 

14. Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy.
Bettencourt M, Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, and Moul JW:
J Urol, 156:1064-1068, 1996.

 

15. Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer patients.
Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, Srivastava S, and Moul JW:
J Urol, 156: 1511-1516, 1996.

 

16. Review of current detection and treatment options.
Bauer JJ, McLeod DG, and Moul JW:
Prostate cancer: Fed Prac Oct, pp 72-90, 1996.

 

17. Prostate cancer: Diagnosis, treatment and experience at one tertiary military medical center, 1989 and 1994.
Bauer JJ, McLeod DG, and Moul JW:
Milit Med, 161:646-653,1996.